Research Journal of Pharmacology and Pharmacodynamics

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Pharmacogenomics: An Overview


Affiliations
1 Government College of Pharmacy, Karad, Tal. - Karad, Dist. - Satara, 415124, State - Maharashtra, India
     

   Subscribe/Renew Journal


To increase the drug response, the pharmacogenomics applicable in pharmacotherapy by studying genomic level of the human being pharmacogenomics examine the role of entire genome in both disease susceptibility and drug response; in an attempt to identify specific genes, human genetic variation RNA and protein expression differences, that are associated with specific diseases and that may be targets for new drugs. Pharmacogenomics show ability to explore not only drug metabolizing polymorphisms but also drug target polymorphism, drug transporter polymorphisms.

 

Many factors influence drug responses including age, gender, body weight, patient health, disease status, diet, smoking, alcohol, and exercise and drug interaction. However despite careful consideration of these factors, there is no guarantee that a given treatment will be effective. It is thought that a major cause for variability in drug responses lies in patient's genetic makeup. Genetic variations can be used to explain inter individual differences in drug response.

 

Pharmacogenomics is the study of how individual's genetic inheritance affects the body's response to drugs. The term comes from the words pharmacology and genomics and is thus the intersection of pharmaceuticals and genetics.

 

Pharmacogenomics holds the promise that drugs might one day be tailor-made for individuals and adapted to each person's own genetic makeup. Environment, diet, age, lifestyle, and state of health all can influence a person's response to medicines, but understanding an individual's genetic makeup to be the key to creating personalized drugs with greater efficacy and safety.

Keywords

Pharmacogenomics, Individual's Genetic Inheritance, Genome, Personalized Drugs.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Evans WE, Relling MV, Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 1999; 286: 487-491.

  • Mancinelli L, Cronin M, Sadee W, Pharmacogenomics: The promise of personalized medicine. AAPS PharmSci, 2000; article 4: 2 (1)

  • Johnson JA, Drug target pharmacogenomics. Am J Pharmacogenomics, 2001; 1: 271-281.

  • Kalow W, Pharmacogenetics and evolution, Pharmacogenetics 2000; 10: 1-3.

  • Leon Shargal et al., Applied Biopharmaceutics and Pharmacokinetics, 2005: 355.

  • Michael Silber B, Pharmacogenomics, Biomarkers, and the Promise of Personalized Medicine, in Pharmacogenomics 2001: 14.

  • Laurinda BH, Ethical Challenges in the Management of Health Information 2001: 275.

  • Leland H, Hartwell et al., Genetics: From Genes to Genomes 2000:113.

  • Peyser PA, Burns TL, Khoury MJ et al., Approaches to Quantify the Genetic Component of and Identify Genes for Complex Traits, in Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease 2004: 43.

  • Brown SM, Kalow W et. al., Essentials of Medical Genomics, 2003: 253.

  • Duret L, Mouchiroud D, Gouy M, Hovergen: a database of homologous vertebrae genes, Nucleic Acids Res, 1994; 22: 2360-2365.

  • Health Insurance Portability and Accountability Act, Pub. L. No. 110 Stat, 1936 (1996): 104-191.

  • Veenstra DL, The Interface between Epidemiology and Pharmacogenomics, in HUMAN GENOME EPIDEMIOLOGY: A SCIENTIFIC FOUNDATION FOR USING GENETIC INFORMATION TO IMPROVE HEALTH AND PREVENT DISEASE, supra note 8: 234.

  • Laviero M et al., Pharmacogenomics: the Promise of Personalized Medicine, 2 AAPS J. 2000; 1, 3, note 7: 201.

  • Kenneth R, Miller, Joseph L, Biology, 2000: 75.

  • U.S. National Library of Medicine, National Institutes of Health, Department of Health & Human Services, Help Me Understand Genetics (February 25, 2005): 11.

  • Hughes HB, Biehl JP, Jones AP, Schmidt LH, Metabolism of isoniazide in man as related to the occurrence of peripheral neuritis. Am Rev Tuberculosis, 1954; 70: 266-273.

  • Motulsky AG, Drug reactions, enzymes and biochemical genetics. JAMA, 1957; 165: 835-837.

  • Bonicke R, Lisboa BP, Erbeddingtheit der intraindividuellen Konstanz der Isoniazidausscheidung beim Menschen. Naturwissenschaften 1957; 44:314.

  • Kalow W, Pharmacogenetics, Heredity and the Response to Drugs. Philadelphia: W. B. Sauders, 1962.

  • Hansen TS, Petersen NE, Iitia A, Blaabjerg O, Petersen PH, Roburst non-radioactive oligonucleotide ligation assay to detect a common point mutation in the CYP2D6 gene causing abnormal drug metabolism. Clin Chem, 1995; 41: 413-418.

  • Shi MM, Bleavins MR, de la Iglesia FA, Technologies for detecting genetic polymorphism in pharmacogenomics, Mol Diagn, 1999; 4: 343-351.

  • Lars N, The Coming Pharmacogenomics Revolution: Tailoring Drugs to Fit Patients' Genetic Profiles, JURIMETRICS J. 2002; 1: 9:43.

  • Lazarou J, Pomeranz BH, Corey PN, Incidence of adverse drug reactions in hospitalized patients, JAMA, 1998; 279: 1200-1205.

  • Sadee W, Finding the right drug for the right patient. Pharm Res, 1998; 15: 959-963.

  • Brookes AJ, The essence of SNPs. Gene, 1999; 234: 177-186.

  • Marshall A, Getting the right dug into the right patient. Nat Biotechnol, 1997; 15: 1249-1252.

  • McCarthy JJ, Hilfiker R, The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol, 2000; 18: 505-508.

  • Veenstra DL, Kollman PA, Modeling protein stability: a theoretical analysis of the stability of T4 lysozyme mutants. Protein Eng, 1997; 10: 789-807.

  • Sadee W, Pharmacogenomics. BMJ, 1999; 319: 1-4.

  • Israel E, Drazen JM, Ligget SB, et al., The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med, 2000; 162: 75-80.

  • Tolle R, Information technology tools for efficient SNP studies. Am J Pharmacogenomics, 2001; 1: 303-314.

  • Cambien F, Poirier O, Nicaud V, et al. Sequence diversity in 36 candidate genes for cardiovascular disease. Am J Hum Genet, 1999; 65: 183-191.

  • Dawson E, New collaborations make pharmacogenomics a SNP. Mol Med Today 1999; 5: 280.

  • Arther ML, Introduction to protein science: Architecture, function and genomics, 2005: 25.

  • Francke U, Foellmer BE, The glucocorticoid receptor gene is in 5q-q32. Genomics, 1989; 4: 610-612.

  • Anderson NG, Anderson L, The human protein index. Clin Chem, 1982; 28: 739-748.

  • Collins FS, The human genome project and the future of medicine.Ann NY Acad Sci, 1999; 882: 42-65.

  • Pfost DR, Boyce-Jacino MT, Grant DM, A SNPshot: pharmacogenetics and the future of therapy. Trends Biotechnol, 2000; 18: 334-338.

  • Burger's Medicinal Chemistry and Drug Discovery, Sixth Edition, Volume 4: 618-632.

  • Roses AD, Pharmacogenomics and practice of medicine nature. 2000; 405: 857-865.

  • Hoffman PC, Lung cancer. Lancet, 2000; 355: 479.

  • Lazarou J, Pomeranz BH, Corey PN, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies, JAMA, 279(15), Apr 1998; 15: 1200-5.

  • Hodgson J, Marshall A, Pharmacogenomics: will the regulators approve? Nature Biotechnology, 1998; 16: 243-246.

  • Pistoi S, Facing your genetic destiny, part II. Scientific American. February 2002: 25.

  • Lee W, Lockhard C, Kim RB, Rothenberg ML, Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development, 2005; 10: 104-111.

  • Lennard L, Gibson BE, Nicole T, Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child, 1993; 69: 577-579.

  • Sayers I, Hall IP, Pharmacogenetic approaches in the treatment of asthma. Curr Allergy Asthma Rep, 2005; 5: 101-108.

  • I. Zineh, T. Gerhard, C.L.Aquilante, A.L.Beitelshees, B.N.Beasley, A.G. Hartzema, Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. The Pharmacogenomics Journal.2004:354-358.

  • Wang HY, Luo M, Tereshchenko IV, et al., A genotyping system capable of simultaneously analyzing >1000 single nucleotide polymorphisms in a haploid genome. Genome Res, 2005;15:276-283.

  • Kalow W, Meyer Urs A, Tyndale RF, Pharmacogenomics, 2008:135-140.

  • Schafer A, Hawkinsan JR, DNA variation and the future of human genetics. Nature biotech 1998;16:33-39.


Abstract Views: 211

PDF Views: 7




  • Pharmacogenomics: An Overview

Abstract Views: 211  |  PDF Views: 7

Authors

Deepali Gharge
Government College of Pharmacy, Karad, Tal. - Karad, Dist. - Satara, 415124, State - Maharashtra, India
Sunil Bavaskar
Government College of Pharmacy, Karad, Tal. - Karad, Dist. - Satara, 415124, State - Maharashtra, India
Todkar Pavan
Government College of Pharmacy, Karad, Tal. - Karad, Dist. - Satara, 415124, State - Maharashtra, India
Pandurang Dhabale
Government College of Pharmacy, Karad, Tal. - Karad, Dist. - Satara, 415124, State - Maharashtra, India

Abstract


To increase the drug response, the pharmacogenomics applicable in pharmacotherapy by studying genomic level of the human being pharmacogenomics examine the role of entire genome in both disease susceptibility and drug response; in an attempt to identify specific genes, human genetic variation RNA and protein expression differences, that are associated with specific diseases and that may be targets for new drugs. Pharmacogenomics show ability to explore not only drug metabolizing polymorphisms but also drug target polymorphism, drug transporter polymorphisms.

 

Many factors influence drug responses including age, gender, body weight, patient health, disease status, diet, smoking, alcohol, and exercise and drug interaction. However despite careful consideration of these factors, there is no guarantee that a given treatment will be effective. It is thought that a major cause for variability in drug responses lies in patient's genetic makeup. Genetic variations can be used to explain inter individual differences in drug response.

 

Pharmacogenomics is the study of how individual's genetic inheritance affects the body's response to drugs. The term comes from the words pharmacology and genomics and is thus the intersection of pharmaceuticals and genetics.

 

Pharmacogenomics holds the promise that drugs might one day be tailor-made for individuals and adapted to each person's own genetic makeup. Environment, diet, age, lifestyle, and state of health all can influence a person's response to medicines, but understanding an individual's genetic makeup to be the key to creating personalized drugs with greater efficacy and safety.

Keywords


Pharmacogenomics, Individual's Genetic Inheritance, Genome, Personalized Drugs.

References